SCHEMBL5328181

SCHEMBL5328181

Cc1nc2n(c(=O)c1CCN1CCC(c3onc4cc(F)ccc34)CC1)CCCC2

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 16/20 0.75
HTR2A P28223 16/20 0.75
HTR1A P08908 8/20 0.75
KCNH2 Q12809 4/20 0.75
HTR2C P28335 3/20 0.75
ADRA1A P35348 3/20 0.75
HRH1 P35367 3/20 0.75
ACHE P22303 3/20 0.75
ADRA2A P08913 2/20 0.75
ADRA2B P18089 2/20 0.75
ADRA2C P18825 2/20 0.75
DRD1 P21728 2/20 0.75
DRD4 P21917 2/20 0.75
DRD5 P21918 2/20 0.75
HTR1D P28221 2/20 0.75
HTR1B P28222 2/20 0.75
HTR7 P34969 2/20 0.75
DRD3 P35462 2/20 0.75
SCN5A Q14524 2/20 0.75
SLC22A2 O15244 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7322886 0.90 DRD2 (0.64) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL1119172 0.88 DRD2 (0.75) DRD2HTR2AHTR1AKCNH2HTR2C
Risperidone SCHEMBL29392548 0.86 DRD2 (1.00) DRD2HTR2AHTR1AKCNH2HTR2C
Risperidone SCHEMBL16965766 0.86 DRD2 (1.00) DRD2HTR2AHTR1AKCNH2HTR2C
Risperidone SCHEMBL5070793 0.86 DRD2 (1.00) DRD2HTR2AHTR1AKCNH2HTR2C
Risperidone SCHEMBL27911 0.86 DRD2 (1.00) DRD2HTR2AHTR1AKCNH2HTR2C
Risperidone SCHEMBL5774262 0.85 DRD2 (0.98) DRD2HTR2AHTR1AKCNH2HTR2C
Risperidone SCHEMBL28382198 0.85 DRD2 (0.98) DRD2HTR2AHTR1AKCNH2HTR2C
SCHEMBL1842717 0.85 HTR2A (0.76) DRD2HTR2AHTR1AKCNH2HTR2C
Risperidone SCHEMBL20578557 0.85 DRD2 (0.98) DRD2HTR2AHTR1AKCNH2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007138462-A2 AQUEOUS ORAL FORMULATIONS OF RISPERIDONE WOCKHARDT LTD (IN) 2007-12-06 WO disclosed
EP-1490090-A4 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS NEW RIVER PHARMACEUTICALS INC (US) 2006-09-20 EP disclosed
EP-1534288-A1 STABLE AQUEOUS SOLUTIONS OF RISPERIDONE AND METHODS FOR THEIR PREPARATION RANBAXY LABORATORIES, LTD. (IN) 2005-06-01 EP disclosed
EP-1490090-A2 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS New River Pharmaceuticals Inc. (US) 2004-12-29 EP disclosed
WO-2004017975-A1 STABLE AQUEOUS SOLUTIONS OF RISPERIDONE AND METHODS FOR THEIR PREPARATION RANBAXY LABORATORIES LIMITED (IN) 2004-03-04 WO disclosed
WO-2003079972-A2 ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS NEW RIVER PARMACEUTICALS INC. (US) 2003-10-02 WO disclosed
EP-1165090-A2 A METHOD OF TREATING BULIMIA NERVOSA AND RELATED EATING DISORDERS BY ADMINISTRATION OF ATYPICAL ANTIPSYCHOTIC MEDICATIONS Children's Hospital Research Foundation (US) 2002-01-02 EP disclosed
EP-1140029-A1 PREPARATION OF MICROPARTICLES HAVING A SELECTED RELEASE PROFILE Alkermes Controlled Therapeutics Inc. II (US) 2001-10-10 EP disclosed
WO-2000054764-A2 A METHOD OF TREATING BULIMIA NERVOSA AND RELATED EATING DISORDERS BY ADMINISTRATION OF ATYPICAL ANTIPSYCHOTIC MEDICATIONS CHILDREN'S HOSPITAL RESEARCH FOUNDATION (US) 2000-09-21 WO disclosed
WO-2000040221-A1 PREPARATION OF MICROPARTICLES HAVING A SELECTED RELEASE PROFILE ALKERMES CONTROLLED THERAPEUTICS INC. II (US) 2000-07-13 WO disclosed
EP-0196132-A2 1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1986-10-01 EP disclosed